Drawing from the PPI and enhanced KEGG analyses, we hypothesize that the therapeutic efficacy of TSAC in breast cancer may be linked to its inhibitory effects on the EGFR/PI3K/Akt signaling pathways. The gene discussed is EGFR; the disease is breast carcinoma.